Clearmind Medicine Initiates U.S. Clinical Trial for Alcohol Use Disorder

Clearmind Medicine Inc. (Nasdaq: CMND) a clinical stage biotech company developing psychedelic-derived treatment solutions, today announced the initiation of its Phase I/IIa clinical trial at the Johns Hopkins University School of Medicine. This study represents the first human trial for the company’s oral drug candidate, CMND-100, for the treatment of Alcohol Use Disorder (AUD).

The trial, which will evaluate the safety, tolerability, and pharmacokinetics of CMND-100, and will obtain early data on CMND-100’s ability to reduce alcohol cravings and consumption, is being led by Dr. Jennifer Ellis and Professor Eric Strain. Other trial sites that help participant recruitment include Yale School of Medicine and IMCA Center (based in Israel).

The trial marks a milestone in the company’s attempt to take innovative treatment options for addiction, depression, anxiety, and weight loss to market.

Alcohol Use Disorder affects about 400 million people worldwide and is responsible for 2.6 million deaths each year, according to the World Health Organization. In the U.S., more than 15% of adults aged 18–25 met the criteria for an AUD in 2023, highlighting the need for more effective therapies.